Serialisation — looking for value-added opportunities
Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.
The European Falsified Medicines Directive (EU FMD) is just months from its enforcement date. Yet, the industry still has a long way to go if compliance is to be achieved.
TraceLink’s Global Drug Supply Safety and Traceability Report, which includes results from a survey of over 600 respondents, found that 88% of CMOs are concerned that equipment shortages will affect their ability, or their customers’ ability, to comply with the regulations. The survey also revealed that 94% of CMOs felt ‘somewhat’ or ‘very prepared’ for serialisation, yet less than half (42%) had not begun preparing.
Staffan Widengren, Director Corporate Projects at Recipharm, discusses the results of the survey and why CMOs should be focusing on the value-added opportunities presented by serialisation.
Do you think CMOs are right to be concerned about potential equipment shortages in the lead up to the EU FMD?
It’s a legitimate concern, vendors are dealing with significant order volumes and having to prioritize larger customers — lead times from machine vendors have increased significantly from order to delivery in the last year. For a standard machine the lead time today is likely to be over 8 months — Recipharm was working to a timescale of less than 6 months when it started its serialisation program. For businesses yet to select a vendor, they will have to opt for standard machines without customization.
78% of CMOs were already working on value-added projects — why do you think CMOs in the EU are so focused on added-value at this stage?
As the investments required of companies working towards serialisation are so high for a compliance requirement, CMOs are looking for areas where they could gain and add value both internally and for their customers. Developing means of interpreting and utilizing the big data being generated to make improvements in efficiency is a top priority for many.
Why do you think CMOs felt prepared for serialisation despite not having begun any actual preparations?
There’s little doubt that CMOs are aware of the requirement and have begun planning in some way. However, as the serialisation challenge is completely new, there has been some naivety from many businesses and many have failed to appreciate the preparation time required, the lengthening lead times for machines and software from vendors, the complexity of onboarding customers and the difficulty involved in securing approval from top management concerning capex and costs.
Staffan Widengren will be presenting at FutureLink Munich, 5-7 June 2018, on the ‘Final countdown: focus areas for a CDMO before February 2019'.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance